- Telix Pharmaceuticals (TLX) signs a partnership for prostate cancer treatment with RefleXion Medical
- The parties agreed to sign a co-development and commercialisation agreement to expand the use of Telix’s prostate cancer imaging agent Illuccix with the RefleXion platform to guide external-beam radiotherapy in real-time
- Under the agreement, Telix and RefleXion will conduct and co-fund a radiotherapy clinical program using Illuccix as a biological guide and will seek commercialisation in the US
- Telix says the partnership demonstrates the potential for Illuccix and other molecularly-targeted imaging agents in its pipeline to be used as a tool to detect the presence of metastatic disease
- Telix Pharmaceuticals dips 1.72 per cent, trading at $3.99 at 1:09 pm AEST
Telix Pharmaceuticals (TLX) has signed a partnership for prostate cancer treatment with RefleXion Medical.
The parties agreed to sign a co-development and commercialisation agreement to expand the use of Telix’s prostate cancer imaging agent Illuccix with the RefleXion biology-guided radiotherapy (BgRT) platform to guide external-beam radiotherapy in real-time.
BgRT is the only treatment designed to integrate positron-emission tomography (PET) technology as part of external-beam radiotherapy delivery. It uses tracers to signal the location of cancer and guide the delivery of radiotherapy to tumours in real time.
The new contract builds on an existing strategic collaboration between the companies.
Under the agreement, Telix and RefleXion will conduct and co-fund a BgRT clinical program using Illuccix as a biological guide. Through the deal, the parties will seek regulatory approval and jointly pursue commercialisation, starting in the US.
The parties have then agreed to share any upside generated if successfully commercialised.
The agreement also includes the potential to expand the exclusive relationship beyond America.
Dr Christian Behrenbruch, Group CEO of Telix Pharmaceuticals, said Telix is pleased to expand its relationship with RefleXion and move ahead with a clinical program with the objective of regulatory approval of Illuccix for BgRT.
“This partnership demonstrates the potential for Illuccix and other molecularly-targeted imaging agents in our pipeline to be used as a tool to both detect the presence of metastatic disease and guide treatment using innovative complementary technologies such as BgRT,” he said.
The clinical program is expected to commence in 2023.
Telix Pharmaceuticals dipped 1.72 per cent, trading at $3.99 at 1:09 pm AEST.